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Abstract Clinical trials have shown that adjuvant Zole-
dronic acid (ZOL) reduces the development of bone
metastases irrespective of ER status. However, post-
menopausal patients show anti-tumour benefit with ZOL
whereas pre-menopausal patients do not. Here we have
developed in vivo models of spontaneous ER?ve breast
cancer metastasis to bone and investigated the effects of
ZOL and oestrogen on tumour cell dissemination and
growth. ER?ve (MCF7, T47D) or ER-ve (MDA-MB-231)
cells were administered by inter-mammary or inter-cardiac
injection into female nude mice ± estradiol. Mice were
administered saline or 100 lg/kg ZOL weekly. Tumour
growth, dissemination of tumour cells in blood, bone and
bone turnover were monitored by luciferase imaging, his-
tology, flow cytometry, two-photon microscopy, micro-CT
and TRAP/P1NP ELISA. Estradiol induced metastasis of
ER?ve cells to bone in 80–100 % of animals whereas bone
metastases from ER-ve cells were unaffected. Adminis-
tration of ZOL had no effect on tumour growth in the fat
pad but significantly inhibited dissemination of ER?ve
tumour cells to bone and frequency of bone metastasis.
Estradiol and ZOL increased bone volume via different
mechanisms: Estradiol increased activity of bone forming
osteoblasts whereas administration of ZOL to estradiol
supplemented mice decreased osteoclast activity and
returned osteoblast activity to levels comparable to that of
saline treated mice. ER-ve cells require increased osteo-
clast activity to grow in bone whereas ER?ve cells do not.
Zol does not affect ER?ve tumour growth in soft tissue,
however, inhibition of bone turnover by ZOL reduced
dissemination and growth of ER?ve breast cancer cells in
bone.
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Introduction
Oestrogen receptor positive breast cancer accounts for
approximately 70 % of primary breast malignancies. The
development of targeted hormonal and biological therapies
have resulted in significant increases in survival, however
progression to metastasis remains a substantial clinical
problem. Around 65–70 % of cancers that metastasise to
bone are ER?ve and this condition remains incurable [1].
Due to the lack of clinically relevant models for ER?ve
breast cancer bone metastasis the vast majority of pre-
clinical studies have used hormone receptor negative cell
lines to investigate breast cancer dissemination and growth
in bone [reviewed in 2 and 3]. We have established in vivo
models of spontaneous bone metastasis from ER?ve
MCF7 and T47D cells grown in mouse mammary fat pads.
These new models have enabled us, for the first time, to
investigate some of the fundamental steps of bone metas-
tasis following inoculation of cell lines into hind mammary
fat pads, including growth at the primary site, tumour cell
dissemination into the circulation and colonisation and
growth in the bone microenvironment. We are now using
these models to investigate the effects of bone targeted
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therapies on spontaneous bone metastasis of ER?ve
xenografts.
There is increasing clinical and pre-clinical evidence
supporting anti-tumour effects of the anti-resorptive agent
zoledronic acid (ZOL) in hormone receptor negative breast
cancer, but the effects on ER?ve breast cancers remain to
be elucidated. Recent clinical trials suggest that meno-
pausal status, rather than the hormone receptor status of the
tumour, determines the anti-cancer efficiency of ZOL. The
AZURE (Does Adjuvant zoledronic acid reduce Recur-
rence in stage II/III breast cancer?) trial [4] study investi-
gated the use of adjuvant ZOL alongside chemotherapy in
women with high risk of breast cancer recurrence. 3360
women were randomised to receive either placebo or
intensive treatment with ZOL, in addition to standard
therapy. Approximately 78 % of patients in each group had
ER?ve tumours [5] and there was no correlation between
hormone receptor status, disease free survival (DFS) or risk
of death (ROD). In contrast, women who were post-
menopausal for at least 5-years before entering the trial had
a significantly increased disease free survival (25 %) and
reduced risk of death from any cause (26 %) [6]. These
data were confirmed in the ABCSG-12 trial that showed
increased DFS in women more than age 40 who received
ZOL. However the ABCSC-12 study also presented evi-
dence indicating that adjuvant use of ZOL improves the
outcome of pre-menopausal patients with ER?ve tumours
[7], although patients in this trial received goserelin, a
superantagonist of oestrogen, whereas participants in the
AZURE study did not.
The differences in anti-tumour effects of ZOL between
pre-menopausal and post-menopausal patients with bone
metastasis are likely to be influenced by the regulation of
bone turnover by oestrogens. Oestrogen has profound
effects on bone by inhibiting osteoclastogenesis and pro-
moting osteoclast apoptosis via direct actions on osteo-
clasts and their precursors [8–13]. In addition, oestrogens
act on cells of the osteoblast lineage to prevent production
of osteoclastigenic cytokines as well as inhibiting osteo-
clast apoptosis [10–13]. ZOL also exerts pro-apoptotic
effects on osteoclasts through inhibition of key enzymes in
the mevalonate pathway, ultimately preventing the release
of bone derived factors that may stimulate tumour growth
[14]. In contrast to oestrogen, administration of ZOL also
reduces the number and activity of bone forming osteo-
blasts [15]. It is therefore possible that ZOL may be a more
effective anti-tumour agent in a low oestrogen bone
microenvironment due to its ability to inhibit the increased
activity of osteoclasts observed under these conditions.
We have recently used a mouse model that mimics the
pre- and post-menopausal bone microenvironment to
establish the effects of anti-resorptive agents on ER-ve
MDA-MB-231 breast tumour growth in bone. In this model,
reduced circulating oestrogen caused by ovariectomy
resulted in increased osteoclastic bone resorption that trig-
gered the growth of dormant disseminated tumour cells to
form overt tumours in bone. Administration of ZOL, or the
specific osteoclast inhibitor OPG-Fc, prevented ovariec-
tomy-induced stimulation of ER-ve tumour growth in bone,
providing evidence that this process is driven by osteoclast
mediated mechanisms [16, 17]. Interestingly, injection of
ER?ve MCF7 cells into mice with high osteoclast activity
did not induce tumour growth in bone [16]. We do not know
if absence of tumour growth under these conditions was due
to ER?ve tumour cells requiring oestrogen for growth and/
or if different mechanisms are responsible for ER?ve and
ER-ve breast cancer growth in bone.
In the current study we have investigated the effects of
high levels of oestrogen on ER?ve tumour growth and
spontaneous metastasis to bone, as well as on the ability of
ER? and ER-ve breast cancer cells to form tumours in
bone. We have carried out detailed analysis of bone and
tumour growth following administration of ZOL to mice
supplemented with estradiol compared to control, to
investigate the anti-tumour effects of ZOL in a high
oestrogen environment. As expected, ER?ve breast cancer
cells required addition of oestrogen to grow and metasta-
sise to bone. Importantly, this study provides the first
evidence that growth of ER?ve and ER-ve breast cancer
cells in bone is stimulated by different mechanisms:
ER?ve cells require active bone turnover but do not need
increased osteoclasts activity, whereas ER-ve cells require
stimulation of osteoclastic resorption of bone to grow in
this environment. Furthermore, inhibition of bone turnover
by ZOL reduced spontaneous metastasis of ER?ve breast
cancer cells from the mammary fat pad to bone as well as
dissemination and growth of ER?ve tumour cells in bone.
Materials and methods
Cell culture
Human breast cancer cells, MDA-MB-231-luc2 tdTomato
(Calliper Life Sciences, Cheshire, UK), MCF7 and T47D
(European Collection of Cell Cultures, Wiltshire, UK) were
stably transfected with luc-2 using lentiviral transfection
systems (Promega, Life sciences). Prior to in vivo inocu-
lation cells were incubated for 15 min with 25 lM of
1,10-Dioctadecyl-0,30-Tetramethylindodicarbocyanine,
4-Chlorobenzenesulfonate (DiD) (Life Technologies, Pais-
ley, UK). Tumour growth was monitored using an IVIS
(luminol) system (Calliper Life Sciences). Human osteo-
blast-like HS5 cells were obtained from European Collec-
tion of Cell Cultures. All cell types were maintained in
DMSO supplemented with 10 % FCS (Gibco, Paisley, UK).
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Analysis of pro-metastatic parameters in vitro
All experiments were carried out in triplicate and repe-
ated three times. Preliminary experiments were carried
out to find optimum serum concentrations for obtaining
cell growth at conditions 50 % of their maximum rate
and this dose was used for cell proliferation experiments.
Effects of PBS (control), 25, 50 or 100 lM ZOL on
proliferation of HS5, MCF7 and T47D cells was per-
formed in DMSO supplemented with 5 % FCS monitored
every 24 h for 96 h by cell counting with a 1/400 mm2
haemocytometer (Hawksley, UK). Migration and invasion
of MCF7 and T47D cells treated with ZOL/or towards
HS5 cells treated with ZOL, PBS or 10 lg/ml mitomycin
C (control) was assessed using 6 mm Transwell plates
with an 8.0 lm pore size (Costar, Corning Incorporated,
USA) uncoated or coated with matrigel (Invitrogen).
MCF7 or T47D cells were seeded into the inner chamber
at a density of 5 9 105 per assay in DMSO supple-
mented with 2.5 % FCS and HS5 cells in DMSO sup-
plemented with 2.5 % FCS treated with 15 lM ZOL,
PBS or 10 lg/ml mitomycin C (control) added to the
outer chamber. 24 after seeding cells were removed from
the top surface of the membrane and cells that had
invaded through the pores were stained with Haema-
toxylin and Eosin. Invasion was calculated as the per-
centage of cells that invaded through matrigel compared
with cells that moved to the underside of uncoated plates
Numbers of cells were counted using a DMRB micro-
scope (Leitz, Germany) and OsteoMeasure XP v1.2.0.1
program (Osteometrics, USA).
In vivo studies
We used 12-week-old female BALB/c nude mice (Charles
River, Kent, UK). Experiments were carried out in accor-
dance with local guidelines and with Home Office approval
under project licence 40/3462, University of Sheffield, UK.
For experiments investigating the effects of estradiol on
ER?ve tumour growth and bone metastasis 17b estradiol
pellets (Innovative Research of America) were implanted
sub-cutaneously into 6 mice and 6 mice were sham oper-
ated (control). 3 days later, 5 9 105 MCF7 or T47D cells
in 20 lL (50 % matrigel (BD Biosciences) 50 % PBS)
were injected into the left and right hind fat pads. This
experiment was repeated twice to ensure reproducibility of
our model.
To investigate the effects of ZOL on primary tumour
growth and bone metastasis, 5 9 105 T47D cells or MDA-
MB-231 cells were injected into the left and right hind
mammary fat pads 3 days after implantation of an estradiol
pellet. 100 lg/kg ZOL [(1-hydroxy-2- (1H-imidazol-1-yl)
ethylene) bisphosphonic acid] (Novartis Pharma AG,
Basel, Switzerland) or PBS control was administered via
intra-peritoneal injection (n = 8 mice/group). Primary
tumour growth was measured twice per week using cal-
lipers (tumour volume = 4/3 pr3, where radius was cal-
culated as (tumour length ? width)/4), bone metastases
were monitored by in vivo luciferase imaging and final
tumour volume was measured on 2 non-serial histological
samples taken from the right tibiae using a Leica RMRB
upright microscope and OsteoMeasure software (Osteo-
metrics, Inc. Dacatur, GA. USA.). 15 additional mice were
used to study the effects of estradiol and ZOL on bone
turnover. Estradiol pellets were implanted subcutaneously
into 10 mice and 5 were non-estradiol control. 3-days after
implantation of the pellet, 5 mice were injected once per
week with 100 lg/kg ZOL the other 5 received PBS con-
trol for 4-weeks. Mice were sacrificed 24 h after their final
injection with ZOL/PBS.
For investigating the effects of estradiol on dissemina-
tion and growth of ER-ve tumour cells in bone, 17b
estradiol pellets were implanted sub-cutaneously into 8
mice and 8 mice were sham operated (control). 3 days
following implantation of estradiol pellet/sham operation
5 9 105 MDA-MB-231 cells were injected into the left
cardiac ventricle and bone metastases were monitored
twice per week by luciferase imaging. Animals were sac-
rificed 4 weeks following injection of tumour cells.
All mice were culled by cardiac exsanguination and
cervical dislocation. Whole blood was stored in heparin/
10 % DMSO at -80 C for subsequent analysis of circu-
lating tumour cells. Serum was stored at -80 C, primary
tumours were fixed in 4 % paraformaldehyde and tibiae
and femurs were fixed in 4 % PFA for lCT analysis before
decalcification in 1 % PFA/0.5 % EDTA and processing
for histology. Bones for two-photon analysis were stored in
OCT at -80 C.
Biochemical analysis
Serum concentrations of TRAP 5b and P1NP were mea-
sured using commercially available ELISA kits: Mouse-
TRAPTM Assay (Immunodiagnostic systems) and Rat/
Mouse P1NP competitive immunoassay kit (Immunodiag-
nostic Systems), respectively.
Microcomputed tomography imaging
Microcomputed tomography analysis was carried out using
a Skyscan 1172 X-ray-computed microtomography scanner
(Skyscan, Aartselar, Belgium) equipped with an X-ray tube
(voltage, 49 kV; current, 200 lA) and a 0.5-mm alu-
minium filter. Pixel size was set to 5.86 lm and scanning
initiated from the top of the proximal tibia as previously
described [11].
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Bone histology
Osteoclasts were detected by toluidine blue and tartrate-
resistant acid phosphatase (TRAP) staining as previously
described [12]. Osteoblasts were identified as mononuclear,
cuboidal cells residing in chains along the bone surface.
The number of osteoclasts/osteoblasts per millimetre of
cortical-endosteal bone surface and trabecular bone sur-
faces and the proportion of bone surface occupied by
osteoclasts/osteoblasts was determined using a Leica
RMRB upright microscope and OsteoMeasure software
(Osteometrics inc.) as previously described [16].
Two-photon microscopy
Tibiae were imaged using a multiphoton confocal micro-
scope (LSM510 NLO upright; Zeiss, Cambridge, UK). DiD
labelled cells were visualised using a 900 nm Chameleon
laser, bone was detected using the 633 nm multiphoton
laser (Coherent, Santa Clara, CA.) and images were
reconstructed in LSM software version 4.2 (Zeiss).
Velocity 3D image analysis software (Zeiss) was used to
count the number of disseminated tumour cells in 2104 lm
(X-axis) 9 2525 lm (Y-axis) 9 100 lm (Z-axis) of the
left proximal tibia just below the growth plate.
Isolation of circulating tumour cells
Whole blood was analysed from each of the 8 mice per
treatment group and parental MCF7 cells were used for
staining controls using the protocol described in Holen
et al. [18], with the exception that the primary antibody
used was anti-human EpCAM antibody directly conjugated
to Phycoerythrin (PE) (Clone 1B7; 1:50; eBioscience,
Hatfield, UK). PE positive cells were plated directly into a
96-well tissue culture plate on a MoFlow High perfor-
mance cell sorter (Beckman Coulter, Cambridge, UK). PE
fluorescence was detected by a 555LP dichroic long pass
and a 580/30 nm band pass filter. Acquisition and analysis
of cells was performed using Summit 4.3 software. Fol-
lowing sorting, cells were cultured in RPMI medium sup-
plemented with 10 % FCS.
Statistical analysis
Linear regression was calculated for ‘slope significance to
non zero’ using R2 and Syx tests. For Kaplan–Meier sur-
vival charts, statistical analysis was by one tailed Mantel–
Haenszel test and log rank test for trend. All other statis-
tical analysis was by one way analysis of variance
(ANOVA) followed by Newman-Keuls multiple compar-
ison test. Data for in vivo experiments are shown as
mean ± SD and for in vitro experiments as mean ± SEM.
Statistical significance was defined as P B 0.05 as calcu-
lated using Graphpad PRISM software. All P values are
two-sided.
Results
ER1ve breast cancer cells metastasise to bone
from the mammary fat pads
We first established two models of ER?ve breast cancer
metastasis to bone by implanting MCF7 or T47D cells into
the two hind mammary fat pads of 12-week old BALB/c
nude mice (Fig. 1). In the absence of estradiol supple-
mentation, tumours grew very slowly reaching only
126.00 ± 29.46 mm3 (MCF7) and 135.33 ± 25.50 mm3
(T47D) by day 56. Implantation of an estradiol pellet
3 days before injection of tumour cells resulted in signifi-
cantly increased tumour growth from both cell lines, with
tumour volumes reaching 194.00 ± 17.34 mm3 for
MCF7 ? estradiol compared with 61.66 ± 20.21 mm3 for
MCF7 control at 42 days, and 196.67 ± 30.61 mm3 for
T47D ? estradiol compared with 101.33 ± 20.74 mm3 for
T47D control at 49 days. All animals supplemented with
estradiol were sacrificed before the pre-planned protocol
end point (day 56) due to rapid loss of C10 % body mass
(Fig. 1a, b). Luciferase imaging and histological analysis
showed that neither MCF7 nor T47D cells metastasised to
the long bones in the absence of estradiol supplementation.
In marked contrast, in the presence of estradiol, bone
metastases were detected in 85 % of mice bearing MCF7
tumours and 65 % of mice bearing T47D tumours
(Fig. 1c). MCF7 and T47D cells specifically metastasised
to the tibiae and femurs and no overt metastasis were
detected elsewhere.
Estradiol does not stimulate growth of ER2ve
breast cancer cells in bone
We have previously demonstrated that estradiol supple-
mentation of BALB/c nude mice leads to significant
increases in bone forming osteoblasts and bone volume, but
does not affect numbers or activity of osteoclasts in tibiae
or femurs, compared with control mice [16]. In these
studies we established that increased bone turnover stim-
ulates growth of ER-ve MDA-MB-231 breast cancer cells
in bone through osteoclast-mediated mechanisms [16, 17].
We have now investigated whether stimulation of bone
metastases from ER-ve MDA-MB-231 cells is specifically
driven by osteoclast activity, or if increased activity of
osteoblasts following estradiol changes to the bone
microenvironment can also stimulate bone metastasis.
Increasing osteoblast activity with estradiol has no effect
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on MDA-MB-231 tumour growth following orthotropic
implantation into mammary fat pads [19]. Furthermore,
inhibiting bone turnover with weekly administration of
100 lg/kg zoledronic acid (ZOL, Fig. 2a) did not alter
MDA-MB-231 tumour growth in this site (Fig. 2b). MDA-
MB-231 cells did not spontaneously metastasise from the
mammary fat pads to bones in this model and therefore
investigations into the effects of estradiol and ZOL on
MDA-MB-231 tumour cell dissemination and bone
metastases were carried out following tumour cell inocu-
lation via intra-cardiac injection. Injection of MDA-MB-
231 cells into the left cardiac ventricle 3-days following
implantation of an estradiol pellet (Fig. 2a) had no effect
on tumour growth in bone (Fig. 2c, d). Tumours grew in
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Fig. 1 Estradiol stimulates ER?ve tumour growth in the mammary
fat pad and bone metastasis in vivo. 12-week old female BALB/c
nude mice (n = 6 per group) were injected with 5 9 105 MCF7 or
T47D cells into the left and right hind mammary fat pads. Panels a,
b show line graphs representing mean ± SD primary tumour growth
(upper panel) and time to morbidity following tumour cell injection is
represented by Kaplan Mayer plots (lower panel) for MCF7 and
T47D cells, respectively. Panel c shows the percentage of mice that
developed spontaneous bone metastases, photographic images and
photomicrographs of Goldners’ stained cross sections of tibiae from
representative mice with (T) and without (N) bone metastasis from
the second experiment 42 days after injection of tumour cells into the
hind mammary fat pads. *P\ 0.05 compared with control
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the bones of 3/8 control mice and 2/8 mice given estradiol
supplementation (Fig. 2c). Two-photon analysis of the
tibiae from these animals showed similar numbers of DiD-
positive, non-proliferating, tumour cells in the marrow
cavity of all mice (Fig. 2e). These data imply that oestro-
gen induced stimulation of osteoblast does not increase
growth of ER-ve breast cancer cells in bone.
ZOL inhibits metastasis of T47D cells to bone
from tumours in the mammary fat pad
Injection of T47D cells into the hind mammary fat pads of
BALB/c nude mice reproducibly resulted in bone
metastases and these mice remained healthier and lived
longer than animals injected with MCF7 cells. We there-
fore used the T47D model to investigate the effects of ZOL
on primary tumour growth and bone metastasis (Fig. 3a).
Weekly administration of 100 lg/kg ZOL starting 3 days
after injection of T47D cells into the two hind fat pads had
no effect on primary tumour growth by day 34 (tumour
volume 155.92 ± 142.86 mm3 in control versus
131.37 ± 117.32 mm3 in ZOL treated mice, Fig. 3b, c).
Analysis of the hind limbs revealed that animals treated
with ZOL had significantly reduced bone metastases
compared with control (Fig. 3b, d, e). Bioluminescence
and histological analysis showed that tumours were present
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Fig. 2 Estradiol ± zoledronic
acid do not effect MDA-MB-
231 tumour growth and bone
metastases. 12-week old female
BALB/c nude mice ± estradiol
received weekly injection with
100 lg/kg zoledronic acid or
saline (control) for 28 days.
3 days after commencement of
estradiol or zoledronic acid/
saline, 5 9 105 MDA-MB-231
cells were injected into the left
cardiac ventricle or into the left
and right hind mammary fat
pads; n = 8 mice per group
(panel a). Panel b shows the
effects of zoledronic acid on
growth of MDA-MB-231 cells
in the mammary fat pads as
tumour volume (mm3) ± SD.
Panel c shows percentage of
mice with tumours growing in
their bones as measured on
histological sections c and
d shows luciferase
images 28 days following
intracardiac injection of ER-ve
MDA-MB-231 cells. DiD
labelled tumour cells in bone
and representative multiphoton
images of non-proliferating
tumour cells (shown in red)
disseminated in bone (shown in
white) are shown in panel (e)
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in the hind limbs of 8/8 saline treated (control) mice and
2/8 mice treated weekly with 100 lg/kg ZOL (Fig. 3b, d),
with a mean tumour bioluminescence per leg of
1.35 ± 0.54 p/s in control mice and 0.28 ± 0.44 p/s in
ZOL treated mice (P\ 0.001) (Fig. 3e). Histological
analysis confirmed reduced tumour load in bones of mice
treated with ZOL compared with control mice, with aver-
age tumour area measuring 2.50 ± 1.02 in control mice
and 0.25 ± 0.35 in ZOL treated mice (P\ 0.001)
(Fig. 3f). There was no correlation between the volume of
tumours in mammary fat pads and bone metastases
(Fig. 3g). These data show that administration of ZOL
decreased numbers of mice that develop bone metastases
and reduced the size of these tumours in bone compared to
control. This reduction in bone metastasis was not the
result of ZOL affecting primary tumour volume.
Effects of ZOL on ER1ve circulating
and disseminated tumour cells
As ZOL reduced numbers of detectable bone metastases
from T47D tumours, we investigated whether this effect
was associated with alterations in numbers of tumour cells
that were available to generate metastasis. Flow cytometric
analysis of EpCAM positive cells isolated from whole
blood of mice bearing T47D mammary tumours showed a
trend towards fewer circulating tumour cells in ZOL trea-
ted mice (13.00 ± 6.66 per ml/mouse) compared with
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bone metastasis from T47D
cells. Estradiol pellets were
implanted subcutaneously into
12-week old female BALB/c
nude mice after 3 days 5 9 105
T47D cells were injected into
the left and right mammary fat
pads (i.m), mice were left for
3-days before receiving weekly
administration of 100 lg/kg
zoledronic acid or saline
(control) for 28 days; n-8 mice
per group (panel a). H&E
stained scanned images of T47D
tumours extracted from the right
hind fat pad of mice treated
weekly with saline or 100 lg/kg
zoledronic acid and luciferase
images for the right tibiae and
femurs from the same animals
are shown in panel (b). Panel
c shows the mean tumour
volume ± SD in the hind
mammary fat pads and panel
d shows the percentage of mice
that developed bone metastases.
Panels e and f show the mean
tumour area per leg ± SD as
identified by bioluminescence
(photons per second) and
following measurement on
histological sections
respectively. Panel g shows the
correlation between mean size
of tumour in the two mammary
fat pads and mean size of bone
metastases from the same
animal *P\ 0.05 compared
with control
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control (73.67 ± 40.42 per ml/mouse, P = 0.056)
(Fig. 4a). We next used two-photon microscopy to detect
DiD-labelled tumour cells that had and disseminated to
bone from the mammary pad (Fig. 4b). We detected sig-
nificantly higher numbers of DiD-labelled tumour cells in
the marrow cavity of tibiae from control (saline) treated
mice (4.64 ± 0.15 cells/mm2) compared with mice treated
weekly with 100 lg/kg ZOL (3.87 ± 0.08 cells/mm2
P = 0.02). These data imply that ZOL may affect tumour
cell shedding from the primary site, thereby limiting the
number of tumour cells that are available to colonise bone
and develop into secondary tumours.
Effects of estradiol and ZOL on bone
Estradiol and ZOL both have extensive effects on the bone
environment. Estradiol appears to increase bone volume via
inducing osteoclast apoptosis and prolonging the life of
osteoblasts [8, 9], whereas ZOL has well documented
properties as an anti-resorptive agent targeting osteoclasts
[14]. In order to identify the effects of ZOL on bone turnover
in a high oestrogen environment, we gave 12-week old
female mice continuous estradiol supplementation with or
without weekly administration of 100 lg/kg ZOL for
28-days. uCT analysis of tibiae revealed a significant
increase in bone volume in mice receiving estradiol com-
pared with control animals (BV/TV % = 18.94 ± 0.85 for
control and 56.15 ± 5.24 for estradiol, P B 0.001) which
was further increased in mice receiving estradiol and ZOL to
78.81 ± 2.31 (P = 0.01 compared to estradiol alone and
P B 0.001 compared with control) (Fig. 5a, b). ELISA
analysis showed no differences in serum TRAP levels
between control (12.36 ± 2.76 U/L) and estradiol
(9.96 ± 2.07 U/L) supplemented animals. In contrast,
treating estradiol supplemented mice with ZOL resulted in a
significant reduction in circulating concentrations of TRAP
to 1.44 ± 0.88 U/L (P B 0.001) (Fig. 5c). Supplementation
with estradiol also stimulated osteoblast activity as evident
by a significant increase in circulating concentrations of
P1NP compared with control (P\ 0.001). Administration
of ZOL to estradiol supplemented mice reduced circulating
P1NP concentrations to levels similar to that in control mice
(control 2.93 ± 0.29 ng/ml; estradiol 4.25 ± 0.33; estra-
diol ? ZOL 2.72 ± 0.48 ng/ml) (Fig. 5d). These data show
that ZOL is more effective at reducing osteoclast activity
than osteoblast activity in a high oestrogen environment.
Effects of bone cells – ZOL on migration
and invasion of ER1ve breast cancer cells
We next investigated whether cytostatic concentrations of
ZOL affect tumour cell invasion and migration towards
bone cells in vitro. Initial experiments identified 25 lM
ZOL to be cytostatic and non-toxic in HS5 (osteoblastic),
MCF7 and T47D cells over a 96 h time period (Fig. 6a, c),
without affecting migration or invasion of matrigel by
these tumour cells (data not shown). Treatment of HS5
cells with 25 lM ZOL inhibited the numbers of MCF7 and
T47D cells that migrated towards these HS5 cells
(P = 0.02 for MCF7 and P = 0.03 for T47D cells) and
inhibited invasion of MCF7 and T47D cells through
matrigel towards HS5 cells (P B 0.01 for both MCF7 and
T47D cells) over a 24 h time period (Fig. 6d–g). All data
were compared with migration and invasion of MCF7 and
T47D cells towards control (PBS) treated HS5 cells. To
establish whether reduced migration and invasion was a
result of ZOL decreasing the proliferation of HS5 cells we
used mitomycin C as a control. Treatment of HS5 cells
with mitomycin C had comparable affects on migration and
invasion of MCF7 and T47D cells to that caused by
treatment with ZOL (Fig. 6d–g). These in vitro data indi-
cate that tumour cells have a preference to migrate towards
bone cells that are actively proliferation. Therefore, it is
possible that inhibition of bone turnover by ZOL may
reduce ER?ve breast cancer cell homing to bone from the
primary site in our in vivo models.
Discussion
To date, only a small number of studies have been carried
out investigating the effects of ZOL on ER?ve breast
cancer and parameters associated with metastasis. These
have focused on in vitro models of tumour apoptosis [20,
21] proliferation [22, 23], migration [24, 25] and invasion
[25, 26] and until now there has been no data available
from clinically relevant in vivo models representing
metastasis of human breast cancer cells from the primary
cFig. 4 Zoledronic acid inhibits dissemination of ER?ve tumour cells
in bone. Estradiol pellets were implanted subcutaneously into
12-week old female BALB/c nude mice after 3 days 5 9 105 T47D
cells were injected into the left and right mammary fat pads (i.m),
mice were left for 3-days before receiving weekly administration of
100 lg/kg zoledronic acid or saline (control) for 28 days. N = 8 mice
per group were analysed for tumour cell dissemination into blood and
n = 4 mice per group were used for two-photon analysis of tumour
cell dissemination into the tibiae. Panel a shows the effects of weekly
administration of zoledronic acid on dissemination of T47D cells
form mammary fat pad tumours into the blood. Flow cytometric
histograms show the positive staining profiles and gating strategy.
Mean numbers of circulating tumour cells ± SD were calculated
from numbers of cells observed in R3. Panel b shows representative
multiphoton images of non-proliferating DiD-labelled tumour cells
(shown in red) that have been disseminated into the bone (shown in
white) form the circulation. Mean numbers ± SD of DiD labelled
tumour cells in the tibiae are shown in the histogram. *P\ 0.05
compared with control
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site to bone. For the current study we have used MCF7 and
T47D cells to establish in vivo models of ER?ve breast
cancer bone metastasis. Injection of either MCF7 or T47D
cells into the two hind mammary fat pads of 12-week old
BALB/c nude mice, 3 days after subcutaneous implanta-
tion of a slow release estradiol pellet, resulted in sponta-
neous overt metastasis detected exclusively in long bones
of the hind limbs within 2–3 weeks. All animals supple-
mented with estradiol were sacrificed before control mice
and before the pre-planned protocol endpoint due to loss of
10 % of body mass. Although the size primary tumours in
estradiol supplemented animals were small (135 ±
25.5 mm3 for T47D and 126 ± 29.46 mm3 for T47D) and
did not differ significantly from primary tumours in control
mice estradiol supplemented animals had the additional
burden of bone metastases. It is likely that this additional
tumour burden contributed to accelerated loss of body mass
seen in these animals. Mice bearing T47D tumours
remained healthier for longer and therefore these models
were used for subsequent in vivo experiments. Using these
models, we have shown that administration of a clinically
relevant dose of ZOL (100 lg/kg, equivalent to the 4 mg
clinical dose) once per week reduces the number of tumour
cells that disseminate into the bone environment and
inhibits development of bone metastases. We did not detect
overt metastasis by luciferase imaging in any other bony
sites or soft tissue during the 56 day protocol. However, we
did not perform two-photon analysis in tissues other than
tibiae and femurs and therefore further experiments need to
be carried out into accurately characterise the metastatic
potential of MCF7 and T47D cells in these models.
Our present data suggest that the direct effects of ZOL
on tumour cell proliferation in vitro and in soft tissue
tumours in vivo are similar for both ER?ve and hormone
receptor negative breast cancer cells. Numerous reports
show direct anti-proliferative effects of adding 5–25 lM
ZOL to the media of ER?ve MCF7 and T47D cells as well
as hormone receptor negative MDA-MB-231 and MDA-
MB-436 cells [reviewed in 27, 28]. In the current study we
wanted to mimic the effects of ZOL in the bone environ-
ment. ZOL has high affinity of calcium in bone where it is
preferentially incorporated into sites of active bone
remodelling. In breast cancer patients, this results in mil-
limolar concentrations of ZOL accumulating in bone fol-
lowing a single 4 mg infusion [29] and 60–65 % of this is
retained by the skeleton [30]. As ZOL is directly incor-
porated into the skeleton, this compound has long lasting
effects in this organ and it is estimated that the concen-
tration of bisphosphonates in the resorption lacuna can be
up to 10–1000 lM [31]. We therefore investigated the
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Fig. 5 Estradiol and zoledronic acid on bone have physiological
effects on bone. Estradiol pellets were implanted into 10, 12-week old
female BALB/c nude mice and 5 mice received saline control. 3 days
later 5 estradiol-supplemented mice received 100 lg/kg zoledronic
acid weekly and the remaining animals were administered saline
(control, n = 5 per group). Representative lCT images of tibiae from
mice receiving estradiol supplementation with or without weekly
administration of 100 lg/kg zoledronic acid (a). Panel b shows
effects of estradiol ± zoledronic acid on percentage of bone volume
compared with total tissue volume ± SD. Serum concentrations of
P1NP and TRAP are show in panels c and d, respectively.
***P\ 0.001 compared with control, ^^^P\ 0.001 compared with
estradiol
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effects of 25–100 lM ZOL tumour cell proliferation,
migration and invasion towards HS5 bone cells. In agree-
ment, our current data show that exposure to 25 lM ZOL
inhibits proliferation of MCF7 and T47D cells. There are
no published data relating to the direct anti-tumour effects
of ZOL on ER?ve soft tissue tumours, however, we and
others have consistently shown that administration of
clinically relevant doses of ZOL do not exert anti-tumour
effects on ER-ve soft tissue tumours in vivo [32–35].
Similarly, the current study demonstrated an absence of
anti-tumour activity against ER-ve MDA-MB-231 or
ER?ve MCF7 mammary tumours following weekly
administration of 100 lg/kg ZOL in vivo. It therefore
seems likely that concentrations of ZOL that reach soft
tissue tumours in vivo are not sufficient to affect tumour
growth and any anti-metastatic effects are unlikely to be as
a result of ZOL acting directly on the primary tumour.
ZOL is shown to inhibit migration and invasion of
ER-ve breast cancer cells but has comparatively modest
inhibitory effects on ER?ve cells in vitro [36–38]. In
agreement with this, we found no effects of ZOL on
migration or invasion of MCF7 or T47D cells in vitro (data
not shown). However, addition of either the cytostatic
compound mitomycin C, or 25 lM ZOL, to a transwell
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Fig. 6 Effects of Zoledronic
acid on ER?ve breast cancer
cell migration and invasion
towards bone cells in vitro.
Panels a, b and c show the
effects of 25, 50 and 100 lM
zoledronic acid on proliferation
of HS5 (bone) cells and MCF7
and T47D breast cancer cells
respectively. Effects of 25 lM
ZOL and mitomycin C on HS5
cell induced migration and
invasion of MCF7 cells are
shown in panels (d, f) and
effects on T47D cells are shown
in panels (e, g). *P\ 0.05
compared with control,
$P\ 0.05 compared with
100 lM zoledronic acid and
^P\ 0.05 compared with 100
and 50 lM zoledronic acid
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assay inhibited HS5 (bone cell) stimulated migration and
invasion of MCF7 and T47D cells, suggesting that
repressing proliferation of bone cells inhibits metastatic
potential of ER?ve breast cancer cells. This hypothesis was
supported by our in vivo studies, in which we found a trend
towards decreased numbers of tumour cells being dissem-
inated from primary T47D mammary tumours into the
blood stream of mice treated with ZOL compared with
control (saline) treated mice (P = 0.056). This was
accompanied by a significant decrease in the numbers of
DiD-labelled tumour cells in the tibiae of mice treated with
estradiol and ZOL, compared with mice treated with
estradiol alone. We can not decipher whether lower num-
bers of disseminated DiD-labelled tumour cells in bone are
as a result of fewer available cells in the circulation that
could colonise this site, or whether ZOL induced alterations
to the bone microenvironment make bone less permissive
for ER?ve tumour cell homing and/or colonisation. Inter-
estingly, we have recently shown that a single dose of ZOL
does cause substantial alterations to the areas of the tibia
most commonly colonised by breast cancer cells in BALB/c
nude mice [15]. Although this caused a re-distribution of
ER-ve cancer cells in bone, the total number of tumour
cells was unaffected. However, the model used by Haider
et al. relies on tumour cells being injected directly into the
circulation and therefore does not represent the effects of
ZOL on tumour cell dissemination in bone from a primary
site. It must be noted that extrapolation of numbers of
tumour cells disseminated in bone by counting DiD label-
led cells is likely to be an underestimate. DiD is a lipophilic
membrane dye that is retained by non-proliferating cells
and lost as tumour cells divide [16]. ZOL significantly
inhibited formation of tumours in bone, therefore more
tumour cells that have disseminated in bone will retain DID
in the ZOL treated group at the 4 week time point mea-
sured, compared with control where proliferating tumour
cells will gradually lose the dye and become undetectable.
Whether tumours develop in bone from one or several
disseminated tumour cells remains an unanswered question,
making it difficult to judge the extent to which this affects
our analysis. It is likely that ZOL induced reduction in
numbers of tumour cells that disseminate in bone contribute
to the reduced tumour burden observed in ZOL treated
animals compared with control, however, this is probably
not the only mechanism. We have previously shown that
administration of ZOL or OPG-Fc prevents OVX-induced
growth of dormant breast cancer cells to form overt
tumours in bone, demonstrating that inhibition of activity
of bone cells prevents proliferation of disseminated tumour
cells in this environment [16, 17]. It is possible that some
antitumour effects of ZOL remain unaccounted for in our
model. We have used athymic nude mice that lack T-cells
to allow the growth and metastasis of human cancer cell
lines. There is accumulating evidence suggesting that ZOL
has immunomodulatory properties that may contribute to
the potential anti tumour effects of this compound [39–41].
Unfortunately, there is no immunocompetent model of
ER?ve breast cancer metastasis to bone that will allow us
to study this in more detail, further highlighting the need for
the development of more clinically relevant in vivo models.
Castration-induced bone loss and PTH induced increase
in osteoclasts and osteoblasts stimulate MDA-MB-231
tumour growth in bone [16, 17]. The compensatory
mechanisms coupling activity of osteoclasts and osteo-
blasts makes it difficult to distinguish which cell type is
involved in stimulation of tumourigenesis. In order for
MCF7 or T47D cells to metastasise to bone it was neces-
sary to increase the concentrations of circulating oestrogen
in the mice by implanting a slow release estradiol pellet.
Oestrogen has well defined activity in bone causing
apoptosis in osteoclasts whilst prolonging the life of
osteoblasts [8–13] and analysis of serum and bones from
animals given estradiol supplementation revealed substan-
tial increases in osteoblast activity but no significant
alterations in osteoclast activity. This is in agreement with
our previous data showing increased numbers of osteo-
blasts and no alterations in numbers of osteoclasts in bones
from animals supplemented with estradiol [16]. We
therefore investigated whether these oestrogen-mediated
alterations in bone turnover were responsible for stimu-
lating tumour growth in bone. Injection of hormone
receptor negative MDA-MB-231 cells directly into the
circulation of 12-week old mice supplemented with estra-
diol resulted in tumour cells disseminating in bone, but did
not stimulate tumour formation, suggesting that MDA-MB-
231 cells require osteoclast mediated bone resorption to
proliferate in the bone environment of adult mice. In
contrast, ER?ve cells readily form tumours in this estradiol
high and osteoblast rich environment, but are not stimu-
lated to proliferate in bone under conditions of increased
bone resorption [16]. Administration of ZOL to mice
supplemented with estradiol resulted in significant decrease
in osteoclast activity and restored osteoblast activity to
background (control) levels (Fig. 3c, d). It therefore
appears that either ER?ve breast cancer cells require
increased osteoblast activity to grow in bone, or they can
grow in bone under normal conditions of bone resorption
(requiring estradiol as a growth factor independent of the
bone environment). Our data suggest that decreased bone
turnover following ZOL prevents proliferation of dissem-
inated ER?ve cells in bone, however, the mechanism
behind this has yet to be fully established. Further studies
are now required to decipher which cell types are important
for ER?ve tumour growth in bone and why ZOL appears
to have reduced capacity to inhibit osteoblast activity in a
high oestrogen environment.
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In conclusion, ZOL exerts indirect and direct effects that
inhibit spontaneous bone metastasis from ER?ve mam-
mary tumours. Administration of ZOL does not alter
growth of ER?ve cells at the primary site but reduces
tumour cell dissemination in bone. Once cells have dis-
seminated in the bone environment the ZOL-mediated
reduction in bone turnover prevents tumour cells from
proliferating and forming overt metastases. The mechanism
for stimulating tumour growth in bone appears to be dif-
ferent for hormone receptor negative and ER?ve breast
cancer cells; hormone receptor negative cells require
increased bone resorption to proliferate and form bone
metastases whereas ER?ve cells do not. As both hormone
receptor negative and ER?ve breast cancer cells require
active bone resorption for tumours to grow in this envi-
ronment, we hypothesise that ZOL inhibits tumour growth
in bone form both types of breast cancer by inhibiting bone
turnover. It is therefore likely that ZOL has more potent
effects on tumour growth in patients who are 5-years or
more post menopause as firstly these patients exhibit higher
levels of bone turnover at baseline than pre-menopausal
patients and therefore gain more benefit from anti-resorp-
tive therapy [42] and secondly, ZOL appears to have
increased ability to reduce bone turnover in a low oestro-
gen environment.
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